Discrepancies in estradiol levels in a premenopausal woman receiving abemaciclib despite ovarian function suppression and bilateral salpingo-oophorectomy.
Discrepancies in estradiol levels in a premenopausal woman receiving abemaciclib despite ovarian function suppression and bilateral salpingo-oophorectomy.
复制标题
尽管卵巢功能抑制和双侧输卵管卵巢切除术，但接受 abemaciclib 的绝经前妇女的雌二醇水平存在差异。
DOI：
10.1016/j.cpccr.2023.100224
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Fasano,Julie
中科院分区：
文献类型：
--
作者：
Kessler,AlainaJ;Patel,Rima;Gallagher,EmilyJane;Shao,Theresa;Fasano,Julie
基于monarchE试验，Abemaciclib被批准用于高风险、激素受体阳性、her2阴性早期乳腺癌患者的辅助治疗与内分泌治疗联合使用。绝经前妇女的内分泌治疗选择包括芳香酶抑制剂抑制卵巢功能或他莫昔芬伴或不伴卵巢抑制。我们描述了一个独特的案例，绝经前妇女早期乳腺癌接受辅助abemaciclib和芳香酶抑制剂，尽管化学和手术卵巢功能抑制，但通过雅培Alinity化学发光免疫分析法测量雌二醇水平升高。鉴于双侧输卵管卵巢切除术后使用液相色谱-质谱法检测雌二醇水平较低，我们的病例报告表明abemaciclib与雅培Alinity免疫测定存在干扰。这种可能的干扰对临床护理有重大影响，因为通过免疫分析法测量的雌二醇水平的虚假升高可能导致不必要的治疗改变，包括手术。
Abemaciclib is approved for use in the adjuvant setting in combination with endocrine therapy for patients with high-risk, hormone receptor-positive, HER2-negative early-stage breast cancer based on the monarchE trial. Options for endocrine therapy for premenopausal women include an aromatase inhibitor with ovarian function suppression or tamoxifen with or without ovarian suppression. We describe a unique case of a premenopausal woman with early-stage breast cancer receiving adjuvant abemaciclib and an aromatase inhibitor with elevated estradiol levels as measured by the Abbott Alinity chemiluminescent immunoassay despite chemical and surgical ovarian function suppression. Given low estradiol levels using liquid chromatography-mass spectrometry testing following a bilateral salpingo-oopherectomy, our case report suggests an interference of abemaciclib with the Abbott Alinity immunoassay. This possible interference has significant impacts on clinical care as false elevations in estradiol levels measured by immunoassays can lead to unnecessary treatment changes, including surgery.